Evidence map›Paper›PMID 38396242›Full record

ArticleApplied microbiology and biotechnology2024

An M cell-targeting recombinant L. lactis vaccine against four H. pylori adhesins.

Furui Zhang, Tianyi Shi, Zhen Zhang, Shue Wang, Jing Liu, Yonghong Li, Xuequan Wang, Kunmei Liu, Le Guo

Open access · goldAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026
    Review
  2. Frontiers in immunology · 2026
    Review
  3. Vaccines · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Furui ZhangSchool of Laboratory, Ningxia Medical University, Yinchuan, 750004, China.
Tianyi ShiSchool of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China.
Zhen ZhangDepartment of Geriatrics and Special Needs Medicine, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.
Shue WangSchool of Laboratory, Ningxia Medical University, Yinchuan, 750004, China.
Jing LiuSchool of Laboratory, Ningxia Medical University, Yinchuan, 750004, China.
Yonghong LiSchool of Public Health and Management, Ningxia Medical University, Yinchuan, 750004, China.
Xuequan WangKey Laboratory of Radiation Oncology of Taizhou, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, 317000, China. yantaiquan@126.com.ORCID http://orcid.org/0000-0002-8251-7622
Kunmei LiuSchool of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China. lkm198507@126.com.ORCID http://orcid.org/0000-0002-1018-3336
Le GuoSchool of Laboratory, Ningxia Medical University, Yinchuan, 750004, China. guoletian1982@163.com.ORCID http://orcid.org/0000-0001-9282-7280
Ningxia Medical University · CNWenzhou Medical University · CN

Funding

Director Fund of Ningxia Key Laboratory of Craniocerebral Disease LNZR202304Key R & D Plan Project of Ningxia Autonomous Region 2020BFG02012National Natural Science Foundation of China 32070930National Natural Science Foundation of China 82160497National Natural Science Foundation of China 82360711Natural Science Foundation of Ningxia 2022AAC02034Natural Science Foundation of Ningxia 2023AAC03155Natural Science Foundation of Ningxia 2023AAC03207Science Research Project of Ningxia's Colleges NGY2020043Science Research Project of Ningxia's Colleges NYG2022045
6 · The paper itself

Abstract

The acidic environment and enzyme degradation lead to oral vaccines often having little immune effect. Therefore, it is an attractive strategy to study an effective and safe oral vaccine delivery system that can promote gastrointestinal mucosal immune responses and inhibit antigen degradation. Moreover, the antigens uptake by microfold cells (M cells) is the determining step in initiating efficient immune responses. Therefore, M cell-targeting is one promising approach for enhancing oral vaccine potency. In the present study, an M cell-targeting L. lactis surface display system (plSAM) was built to favor the multivalent epitope vaccine antigen (FAdE) to achieve effective gastrointestinal mucosal immunity against Helicobacter pylori. Therefore, a recombinant Lactococcus lactic acid vaccine (LL-plSAM-FAdE) was successfully prepared, and its immunological properties and protective efficacy were analyzed. The results showed that LL-plSAM-FAdE can secretively express the recombinant proteins SAM-FAdE and display the SAM-FAdE on the bacterial cell surface. More importantly, LL-plSAM-FAdE effectively promoted the phagocytosis and transport of vaccine antigen by M cells in the gastrointestinal tract of mice, and simulated high levels of cellular and humoral immune responses against four key H. pylori adhesins (Urease, CagL, HpaA, and Lpp20) in the gastrointestinal tract, thus enabling effective prevention of H. pylori infection and to some extent eliminating H. pylori already present in the gastrointestinal tract. KEY POINTS: • M-cell-targeting L. lactis surface display system LL- plSAM was designed • This system displays H. pylori vaccine-promoted phagocytosis and transport of M cell • A promising vaccine candidate for controlling H. pylori infection was verified.

Indexed as

Helicobacter InfectionsHelicobacter pyloriLactococcus lactisAdhesins, BacterialAnimalsAntibodies, BacterialAntigens, BacterialBacterial VaccinesM CellsMiceMice, Inbred BALB CVaccines, SyntheticAdhesins, BacterialAntibodies, BacterialAntigens, BacterialBacterial VaccinesVaccines, SyntheticAdhesinH. pyloriM cellRecombinant L. lactisVaccine surface display

Identifiers

PMID38396242
PMCPMC10891252
OpenAlexW4392124397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.